A Retrospective Analysis: A Novel Index Predicts Survival and Risk-Stratification for Bone Destruction in 419 Newly Diagnosed Multiple Myelomas

Onco Targets Ther. 2019 Dec 3:12:10587-10596. doi: 10.2147/OTT.S229122. eCollection 2019.

Abstract

Objective: Multiple myeloma (MM) patients with bone destruction are difficult to restore, so it is of great clinical significance to further explore the factors affecting MM bone destruction.

Methods and results: This study retrospectively analyzed 419 cases with MM. Multiple linear regression analysis showed that those MM patients with a higher concentration of Ca2+ in serum, higher positive rate of CD138 immuno-phenotype and advanced in stage with 13q34 deletion in cytogenetics would be more prone to bone destruction, while total bile acid (TBA) and kappa chain isotope negatively correlated with bone destruction in MM patients. The Kaplan-Meier analysis indicated that Ca2+, serum β2-microglobulin (β2-MG), hemoglobin (HGB), creatinine (CREA), uric acid (UA) and age correlated with the survival of bone destruction in MM patients. Cox regression analysis further showed that the independent prognostic factors of β2-MG and CREA had a higher risk for early mortality in bone destruction patients. Moreover, an index was calculated based on β2-MG and globulin (GLB) to white blood cell (WBC) ratio to predict the poor survival of bone destruction patients.

Conclusion: We provide a novel marker to predict the prognosis of myeloma patients using routine examination method instead of bone marrow aspiration, and provide a reference for clinical evaluation.

Keywords: bone destruction; multiple myeloma; prediction index; prognosis.

Grants and funding

This article was funded by the Research and Innovation Cultivation Fund of Zhongnan Hospital (No. cxpy20160001 and No. cxpy20160012), Research Project of Hubei Provincial Health and Family Planning Commission (No. WJ2017Z009), Key Project of Health Commission of Hubei Province (No. WJ2019H008), Natural Science Foundation of China (NSFC) Program (No. 81770179), and Hong Kong Scholars Program (No. XJ2018060).